<?xml version="1.0" encoding="UTF-8" standalone="no"?>

<MINiML
   xmlns="http://www.ncbi.nlm.nih.gov/geo/info/MINiML"
   xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
   xsi:schemaLocation="http://www.ncbi.nlm.nih.gov/geo/info/MINiML http://www.ncbi.nlm.nih.gov/geo/info/MINiML.xsd"
   version="0.5.0" >

  <Contributor iid="contrib1">
    <Person><First>Vincent</First><Last>Negre</Last></Person>
    <Email>vincent.negre@valdorel.fnclcc.fr</Email>
    <Department>U896</Department>
    <Organization>INSERM</Organization>
    <Address>
      <Line>IRCM CRLC Val d'aurelle</Line>
      <City>Montpellier</City>
      <Zip-Code>34298</Zip-Code>
      <Country>France</Country>
    </Address>
  </Contributor>

  <Contributor iid="contrib2">
    <Person><First>Laurent</First><Last>Journot</Last></Person>
    <Email>mgx@igf.cnrs.fr</Email>
    <Laboratory>Institut de Génomique Fonctionnelle (IGF)</Laboratory>
    <Organization>MGX - Montpellier GenomiX</Organization>
    <Address>
      <Line>141 rue de la Cardonille</Line>
      <City>Montpellier</City>
      <Postal-Code>34094 - Cedex 05</Postal-Code>
      <Country>France</Country>
    </Address>
    <Web-Link>http://www.mgx.cnrs.fr/</Web-Link>
  </Contributor>

  <Contributor iid="contrib3">
    <Person><First>Dany</First><Last>Severac</Last></Person>
  </Contributor>

  <Contributor iid="contrib4">
    <Person><First>Cindy</First><Last>Aknin</Last></Person>
  </Contributor>

  <Contributor iid="contrib5">
    <Person><First>Christelle</First><Last>Dantec</Last></Person>
  </Contributor>

  <Contributor iid="contrib6">
    <Person><First>Maïa</First><Last>Chanrion</Last></Person>
  </Contributor>

  <Contributor iid="contrib7">
    <Person><First>Negre</First><Last>Vincent</Last></Person>
  </Contributor>

  <Contributor iid="contrib8">
    <Person><First>Hélène</First><Last>Fontaine</Last></Person>
  </Contributor>

  <Contributor iid="contrib9">
    <Person><First>Nicolas</First><Last>Salvetat</Last></Person>
  </Contributor>

  <Contributor iid="contrib10">
    <Person><First>Frédéric</First><Last>Bibeau</Last></Person>
  </Contributor>

  <Contributor iid="contrib11">
    <Person><First>Gaëtan</First><Last>MacGrogan</Last></Person>
  </Contributor>

  <Contributor iid="contrib12">
    <Person><First>Louis</First><Last>Mauriac</Last></Person>
  </Contributor>

  <Contributor iid="contrib13">
    <Person><First>Dionyssios</First><Last>Katsaros</Last></Person>
  </Contributor>

  <Contributor iid="contrib14">
    <Person><First>Franck</First><Last>Molina</Last></Person>
  </Contributor>

  <Contributor iid="contrib15">
    <Person><First>Charles</First><Last>Theillet</Last></Person>
  </Contributor>

  <Contributor iid="contrib16">
    <Person><First>Jean-Marie</First><Middle>M</Middle><Last>Darbon</Last></Person>
  </Contributor>

  <Database iid="GEO">
    <Name>Gene Expression Omnibus (GEO)</Name>
    <Public-ID>GEO</Public-ID>
    <Organization>NCBI NLM NIH</Organization>
    <Web-Link>http://www.ncbi.nlm.nih.gov/geo</Web-Link>
    <Email>geo@ncbi.nlm.nih.gov</Email>
  </Database>

  <Platform iid="GPL5049">
    <Status database="GEO">
      <Submission-Date>2007-03-28</Submission-Date>
      <Release-Date>2007-04-10</Release-Date>
      <Last-Update-Date>2010-06-11</Last-Update-Date>
    </Status>
    <Title>MLRG Human 21K V12.0</Title>
    <Accession database="GEO">GPL5049</Accession>
    <Technology>spotted oligonucleotide</Technology>
    <Distribution>non-commercial</Distribution>
    <Organism taxid="9606">Homo sapiens</Organism>
    <Manufacturer>Montpellier Génopole Microarray core facility</Manufacturer>
    <Manufacture-Protocol>
Manufacturing microarrays
The Human Qiagen/Operon Array Ready oligo set Version 2.0 were spotted using the Amersham Biosciences Lucidea Array spotter on aminosilane-coated mirror glass slides (7 Star, Amersham Biosciences). Negative and positive control oligo were also printed into 24 different sectors of each slide. After printing, the slides were stored at room temperature in a dessicator.
    </Manufacture-Protocol>
    <Support>glass</Support>
    <Coating>aminosilane</Coating>
    <Description>
The Human Genome Oligo Set Version 2.0 contains
21,329 70mers representing 21,329 genes obtained
from the UniGene Database Build Hs 147 and the Human
RefSeq Database, both developed and maintained at the
National Center of Biotechnology Information
(www.ncbi.nlm.nih.gov/UniGene). The set also includes
12 unique positive and 12 unique negative controls
provided in 16 replicates in a 384-well plate.
    </Description>
    <Web-Link>http://www.genopole-montpellier-lr.org/PF/transcriptome/index.htm</Web-Link>
    <Contributor-Ref ref="contrib3" position="1" />
    <Contributor-Ref ref="contrib4" position="2" />
    <Contributor-Ref ref="contrib5" position="3" />
    <Contact-Ref ref="contrib2" />
    <Data-Table>
      <Column position="1">
        <Name>ID</Name>
      </Column>
      <Column position="2">
        <Name>Block</Name>
        <Description>The block number on the array</Description>
      </Column>
      <Column position="3">
        <Name>Block Column</Name>
        <Description>Meta column</Description>
      </Column>
      <Column position="4">
        <Name>Block Row</Name>
        <Description>Meta row</Description>
      </Column>
      <Column position="5">
        <Name>Spot Column</Name>
        <Description>Spot Column in the block</Description>
      </Column>
      <Column position="6">
        <Name>Spot Row</Name>
        <Description>Spot row in the block</Description>
      </Column>
      <Column position="7">
        <Name>Plate Number</Name>
        <Description>Number plate in the spotter</Description>
      </Column>
      <Column position="8">
        <Name>384_plate_position</Name>
        <Description>Position of the oligos in the plate</Description>
      </Column>
      <Column position="9">
        <Name>384_plate_number</Name>
        <Description>Plate ID</Description>
      </Column>
      <Column position="10">
        <Name>Oligo_ID</Name>
        <Description>Oligo ID</Description>
      </Column>
      <Column position="11">
        <Name>GB_accession</Name>
        <Description>GeneBank accession</Description>
      </Column>
      <Column position="12">
        <Name>UniGene_ID</Name>
        <Description>Unigene Accession</Description>
      </Column>
      <Column position="13">
        <Name>Gene_Symbol</Name>
        <Description>Gene symbol</Description>
      </Column>
      <Column position="14">
        <Name>Description 1</Name>
      </Column>
      <Column position="15">
        <Name>SEQUENCE</Name>
      </Column>
      <Column position="16">
        <Name>RegSeq</Name>
      </Column>
      <Column position="17">
        <Name>Description 2</Name>
      </Column>
      <Column position="18">
        <Name>GB_LIST</Name>
        <Description>GenBank accession  </Description>
        <Link-Prefix>http://www.ncbi.nlm.nih.gov/nuccore/?term=</Link-Prefix>
        <Link-Delimiter>,</Link-Delimiter>
      </Column>
      <Column position="19">
        <Name>CLONE_ID</Name>
      </Column>
      <Column position="20">
        <Name>SPOT_ID</Name>
      </Column>
    <External-Data rows="22656">
GPL5049-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Platform>

  <Sample iid="GSM249296">
    <Status database="GEO">
      <Submission-Date>2007-12-13</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5011</Title>
    <Accession database="GEO">GSM249296</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
65.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
9
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
NA
      </Characteristics>
      <Characteristics tag="n dich+">
NA
      </Characteristics>
      <Characteristics tag="pn (tnm)">
NA
      </Characteristics>
      <Characteristics>
ER 223
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
26.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cancer
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
26.2
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249296/suppl/GSM249296.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249296-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249524">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5012</Title>
    <Accession database="GEO">GSM249524</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
75.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
13
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
3
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 460
      </Characteristics>
      <Characteristics tag="pr">
28
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
28.1
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
68.5
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249524/suppl/GSM249524.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249524-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249527">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5013</Title>
    <Accession database="GEO">GSM249527</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
76.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
22
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
12
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 45
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
55.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
54.1
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
55.5
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249527/suppl/GSM249527.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249527-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249529">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5014</Title>
    <Accession database="GEO">GSM249529</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
66.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
4
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 235
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
44.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
1.4
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
24
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
44.8
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249529/suppl/GSM249529.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249529-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249530">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5015</Title>
    <Accession database="GEO">GSM249530</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
55.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
22
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 39
      </Characteristics>
      <Characteristics tag="pr">
80
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
99.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
20.8
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249530/suppl/GSM249530.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249530-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249531">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5016</Title>
    <Accession database="GEO">GSM249531</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
57.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 150
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
57.4
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
16.8
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
57.4
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249531/suppl/GSM249531.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249531-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249532">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5017</Title>
    <Accession database="GEO">GSM249532</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
52.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
22
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 75
      </Characteristics>
      <Characteristics tag="pr">
85
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
57.7
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
40.6
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
21.9
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
57.7
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249532/suppl/GSM249532.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249532-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249533">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5018</Title>
    <Accession database="GEO">GSM249533</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
64.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
5
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 26
      </Characteristics>
      <Characteristics tag="pr">
83
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
137.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
35.8
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249533/suppl/GSM249533.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249533-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249534">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5019</Title>
    <Accession database="GEO">GSM249534</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
55.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 79
      </Characteristics>
      <Characteristics tag="pr">
143
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
142.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences)									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249534/suppl/GSM249534.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249534-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249535">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5020</Title>
    <Accession database="GEO">GSM249535</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
51.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
10
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 26
      </Characteristics>
      <Characteristics tag="pr">
210
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
167.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249535/suppl/GSM249535.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249535-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249536">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5021</Title>
    <Accession database="GEO">GSM249536</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
73.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
NA
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
31
      </Characteristics>
      <Characteristics tag="n+">
29
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 34
      </Characteristics>
      <Characteristics tag="pr">
128
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
39.4
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
2.4
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
39.4
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249536/suppl/GSM249536.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249536-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249537">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5022</Title>
    <Accession database="GEO">GSM249537</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
78.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
NA
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 192
      </Characteristics>
      <Characteristics tag="pr">
67
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
46.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
37.1
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
13.7
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
46.4
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249537/suppl/GSM249537.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249537-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249538">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5023</Title>
    <Accession database="GEO">GSM249538</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
86.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
22
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
NA
      </Characteristics>
      <Characteristics tag="n dich+">
NA
      </Characteristics>
      <Characteristics tag="pn (tnm)">
NA
      </Characteristics>
      <Characteristics>
ER 100% imm
      </Characteristics>
      <Characteristics tag="pr">
40% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
18
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
32.7
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
18
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249538/suppl/GSM249538.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249538-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249539">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5024</Title>
    <Accession database="GEO">GSM249539</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
66.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
13
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
7
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 316
      </Characteristics>
      <Characteristics tag="pr">
134
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
19.9
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249539/suppl/GSM249539.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249539-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249540">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5025</Title>
    <Accession database="GEO">GSM249540</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
58.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
22
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
12
      </Characteristics>
      <Characteristics tag="n+">
6
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 174
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
46.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
6.7
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
46.1
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249540/suppl/GSM249540.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249540-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249541">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5026</Title>
    <Accession database="GEO">GSM249541</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
66.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
10
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
20
      </Characteristics>
      <Characteristics tag="n+">
19
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 234
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
50.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
39.4
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
1.4
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
50.2
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249541/suppl/GSM249541.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249541-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249542">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5027</Title>
    <Accession database="GEO">GSM249542</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
77.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 306
      </Characteristics>
      <Characteristics tag="pr">
182
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
154.9
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
48.8
      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249542/suppl/GSM249542.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249542-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249543">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5028</Title>
    <Accession database="GEO">GSM249543</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
83.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 136
      </Characteristics>
      <Characteristics tag="pr">
255
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
48
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
38.8
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
40.3
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
48
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249543/suppl/GSM249543.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249543-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249544">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5029</Title>
    <Accession database="GEO">GSM249544</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
52.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
NA
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
27
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 158
      </Characteristics>
      <Characteristics tag="pr">
216
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
71.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
7.8
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249544/suppl/GSM249544.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249544-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249545">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5030</Title>
    <Accession database="GEO">GSM249545</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
56.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
19
      </Characteristics>
      <Characteristics tag="n+">
5
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 79
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.9
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249545/suppl/GSM249545.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249545-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249546">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5031</Title>
    <Accession database="GEO">GSM249546</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
75.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
22
      </Characteristics>
      <Characteristics tag="n+">
12
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 15
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
34.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
44.4
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
17.1
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
34.2
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249546/suppl/GSM249546.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249546-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249547">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5032</Title>
    <Accession database="GEO">GSM249547</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
77
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
4
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 41
      </Characteristics>
      <Characteristics tag="pr">
49
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
58.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
17.1
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
58.4
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249547/suppl/GSM249547.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249547-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249548">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5033</Title>
    <Accession database="GEO">GSM249548</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
57.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
NA
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
45
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
23
      </Characteristics>
      <Characteristics tag="n+">
23
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 479
      </Characteristics>
      <Characteristics tag="pr">
16
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
79.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
35
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
48
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
79.8
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249548/suppl/GSM249548.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249548-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249549">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5034</Title>
    <Accession database="GEO">GSM249549</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
69.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
21
      </Characteristics>
      <Characteristics tag="n+">
8
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 175
      </Characteristics>
      <Characteristics tag="pr">
103
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
83.3
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
31.7
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
83.3
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249549/suppl/GSM249549.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249549-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249551">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5035</Title>
    <Accession database="GEO">GSM249551</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
57.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
6
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 33
      </Characteristics>
      <Characteristics tag="pr">
234
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
25.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
48.5
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
13.6
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
25.9
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249551/suppl/GSM249551.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249551-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249552">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5036</Title>
    <Accession database="GEO">GSM249552</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
72.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
12
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
12
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 260
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
106.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
12.4
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249552/suppl/GSM249552.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249552-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249553">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5037</Title>
    <Accession database="GEO">GSM249553</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
64.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
19
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 107
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
152
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249553/suppl/GSM249553.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249553-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249555">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5038</Title>
    <Accession database="GEO">GSM249555</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
71.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
22
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
21
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 26
      </Characteristics>
      <Characteristics tag="pr">
11
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
82.1
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249555/suppl/GSM249555.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249555-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249556">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5039</Title>
    <Accession database="GEO">GSM249556</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
78.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
17
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 68
      </Characteristics>
      <Characteristics tag="pr">
159
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
60.7
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
56.5
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cancer
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
60.7
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249556/suppl/GSM249556.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249556-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249557">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5040</Title>
    <Accession database="GEO">GSM249557</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
54.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
23
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 33
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
38.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
11.4
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
38.2
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249557/suppl/GSM249557.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249557-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249558">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5041</Title>
    <Accession database="GEO">GSM249558</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
73.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
17
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
7
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 98
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
50.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
26.8
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
0.1
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
50.4
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249558/suppl/GSM249558.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249558-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249559">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5042</Title>
    <Accession database="GEO">GSM249559</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
56.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
17
      </Characteristics>
      <Characteristics tag="n+">
16
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 108
      </Characteristics>
      <Characteristics tag="pr">
21
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
74.5
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
50.3
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
34
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
74.5
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249559/suppl/GSM249559.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249559-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249560">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5043</Title>
    <Accession database="GEO">GSM249560</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
57.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
12
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
5
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
16
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
60.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
40.5
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
46.4
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
60.8
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249560/suppl/GSM249560.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249560-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249561">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5044</Title>
    <Accession database="GEO">GSM249561</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
58.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
19
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 194
      </Characteristics>
      <Characteristics tag="pr">
56
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
86.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
14.4
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249561/suppl/GSM249561.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249561-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249563">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5046</Title>
    <Accession database="GEO">GSM249563</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
52.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
18
      </Characteristics>
      <Characteristics tag="n+">
5
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 13
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
69.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
13.4
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
69.4
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249563/suppl/GSM249563.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249563-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249564">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5047</Title>
    <Accession database="GEO">GSM249564</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
73.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
NA
      </Characteristics>
      <Characteristics tag="n dich+">
NA
      </Characteristics>
      <Characteristics tag="pn (tnm)">
NA
      </Characteristics>
      <Characteristics>
ER 60
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
60.6
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
56.1
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
14.5
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
60.6
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249564/suppl/GSM249564.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249564-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249565">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5048</Title>
    <Accession database="GEO">GSM249565</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
60.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
12
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
21
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 37
      </Characteristics>
      <Characteristics tag="pr">
21
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
100.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
46.1
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249565/suppl/GSM249565.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249565-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249566">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5049</Title>
    <Accession database="GEO">GSM249566</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
62.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
18
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 52
      </Characteristics>
      <Characteristics tag="pr">
45
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
57.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cancer
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
57.2
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249566/suppl/GSM249566.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249566-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249567">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5050</Title>
    <Accession database="GEO">GSM249567</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
73.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
21
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 135
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
92.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
48.4
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249567/suppl/GSM249567.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249567-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249595">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5051</Title>
    <Accession database="GEO">GSM249595</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
71
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
32
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 91
      </Characteristics>
      <Characteristics tag="pr">
137
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
81.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249595/suppl/GSM249595.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249595-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249596">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5052</Title>
    <Accession database="GEO">GSM249596</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
71.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
11
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 64
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
99.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
0
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
99.1
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249596/suppl/GSM249596.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249596-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249597">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5053</Title>
    <Accession database="GEO">GSM249597</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
53.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
29
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
24
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 42
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
99.1
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
47.2
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
67.5
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249597/suppl/GSM249597.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249597-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249598">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5054</Title>
    <Accession database="GEO">GSM249598</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
70.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
31
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
21
      </Characteristics>
      <Characteristics tag="n+">
5
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 12
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
72.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
20.4
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
26.1
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
72.2
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249598/suppl/GSM249598.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249598-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249599">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5055</Title>
    <Accession database="GEO">GSM249599</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
59.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
NA
      </Characteristics>
      <Characteristics tag="pt (tnm)">
ND
      </Characteristics>
      <Characteristics tag="lymph node checked">
21
      </Characteristics>
      <Characteristics tag="n+">
4
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 46
      </Characteristics>
      <Characteristics tag="pr">
10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
39.5
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
46.1
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
3.6
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
39.5
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249599/suppl/GSM249599.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249599-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249600">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5056</Title>
    <Accession database="GEO">GSM249600</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
56.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
28
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 53
      </Characteristics>
      <Characteristics tag="pr">
108
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
107.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
35.9
      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249600/suppl/GSM249600.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249600-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249601">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5057</Title>
    <Accession database="GEO">GSM249601</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
79.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
16
      </Characteristics>
      <Characteristics tag="n+">
12
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 441
      </Characteristics>
      <Characteristics tag="pr">
16
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
43.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
94.8
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
1.8
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
43.1
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249601/suppl/GSM249601.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249601-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249602">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5058</Title>
    <Accession database="GEO">GSM249602</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
67.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 54
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
48.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
41.3
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
13.2
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
48.4
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249602/suppl/GSM249602.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249602-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249603">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>EB5059</Title>
    <Accession database="GEO">GSM249603</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
59.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray + Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
4
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 11
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
51.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
35.2
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
51.9
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249603/suppl/GSM249603.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249603-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249604">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4051</Title>
    <Accession database="GEO">GSM249604</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
70.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 15% imm
      </Characteristics>
      <Characteristics tag="pr">
15% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
95.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
15.5
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249604/suppl/GSM249604.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249604-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249605">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4068</Title>
    <Accession database="GEO">GSM249605</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
74.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 70% imm
      </Characteristics>
      <Characteristics tag="pr">
70% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
86.9
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249605/suppl/GSM249605.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249605-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249606">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4070</Title>
    <Accession database="GEO">GSM249606</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
72.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
23
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 80% imm
      </Characteristics>
      <Characteristics tag="pr">
80% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
87.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
31.9
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249606/suppl/GSM249606.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249606-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249607">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4072</Title>
    <Accession database="GEO">GSM249607</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
65.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
19
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 80% imm
      </Characteristics>
      <Characteristics tag="pr">
80% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
82.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249607/suppl/GSM249607.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249607-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249608">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4073</Title>
    <Accession database="GEO">GSM249608</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
50.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
22
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 90% imm
      </Characteristics>
      <Characteristics tag="pr">
90% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
81.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249608/suppl/GSM249608.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249608-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249609">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4076</Title>
    <Accession database="GEO">GSM249609</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
78.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
14
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 60% imm
      </Characteristics>
      <Characteristics tag="pr">
60% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
76.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249609/suppl/GSM249609.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249609-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249610">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4082</Title>
    <Accession database="GEO">GSM249610</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
51.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
13
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 50% imm
      </Characteristics>
      <Characteristics tag="pr">
50% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
71.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249610/suppl/GSM249610.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249610-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249611">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4085</Title>
    <Accession database="GEO">GSM249611</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
71.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 90% imm
      </Characteristics>
      <Characteristics tag="pr">
90% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
71
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249611/suppl/GSM249611.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249611-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249612">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4089</Title>
    <Accession database="GEO">GSM249612</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
79.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
40
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT4
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
NA
      </Characteristics>
      <Characteristics tag="n dich+">
NA
      </Characteristics>
      <Characteristics tag="pn (tnm)">
NA
      </Characteristics>
      <Characteristics>
ER 70% imm
      </Characteristics>
      <Characteristics tag="pr">
70% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
45.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249612/suppl/GSM249612.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249612-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249613">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4091</Title>
    <Accession database="GEO">GSM249613</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
69.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
11
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 70% imm
      </Characteristics>
      <Characteristics tag="pr">
70% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
69.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
32.3
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249613/suppl/GSM249613.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249613-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249614">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>ET4094</Title>
    <Accession database="GEO">GSM249614</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
60.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 95% imm
      </Characteristics>
      <Characteristics tag="pr">
95% imm
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249614/suppl/GSM249614.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249614-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249615">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA4009</Title>
    <Accession database="GEO">GSM249615</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
50.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
17
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 81
      </Characteristics>
      <Characteristics tag="pr">
375
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
136
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
25.6
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
136
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249615/suppl/GSM249615.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249615-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249616">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA4148</Title>
    <Accession database="GEO">GSM249616</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
68.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ICC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 179
      </Characteristics>
      <Characteristics tag="pr">
78
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
42
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
110.4
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
1.6
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
42
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249616/suppl/GSM249616.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249616-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249617">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA4200</Title>
    <Accession database="GEO">GSM249617</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
61.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
Other
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
NA
      </Characteristics>
      <Characteristics tag="pt (tnm)">
NA
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
3
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 109
      </Characteristics>
      <Characteristics tag="pr">
15
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
118.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
40.4
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
118.5
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249617/suppl/GSM249617.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249617-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249618">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA4261</Title>
    <Accession database="GEO">GSM249618</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
73.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 100
      </Characteristics>
      <Characteristics tag="pr">
162
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
147.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249618/suppl/GSM249618.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249618-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249619">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA4496</Title>
    <Accession database="GEO">GSM249619</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
46.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam+LHRH
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
12
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 10
      </Characteristics>
      <Characteristics tag="pr">
139
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
145.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249619/suppl/GSM249619.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249619-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249620">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA5084</Title>
    <Accession database="GEO">GSM249620</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
80
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
NA
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
14
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 219
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
137.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249620/suppl/GSM249620.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249620-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249622">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA5086</Title>
    <Accession database="GEO">GSM249622</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
53
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
Other
      </Characteristics>
      <Characteristics tag="sbr grade">
NA
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 13
      </Characteristics>
      <Characteristics tag="pr">
146
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
107.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
112
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249622/suppl/GSM249622.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249622-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249623">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA5284</Title>
    <Accession database="GEO">GSM249623</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
45.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam+LHRH
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 16
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
135.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249623/suppl/GSM249623.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249623-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249624">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA5345</Title>
    <Accession database="GEO">GSM249624</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
76.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
NA
      </Characteristics>
      <Characteristics tag="pt (tnm)">
NA
      </Characteristics>
      <Characteristics tag="lymph node checked">
3
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
21
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
3.3
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
68.9
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249624/suppl/GSM249624.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249624-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249625">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA5387</Title>
    <Accession database="GEO">GSM249625</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
56
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 12
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
134.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
65.7
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249625/suppl/GSM249625.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249625-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249627">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA5678</Title>
    <Accession database="GEO">GSM249627</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
65.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
5
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 178
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
131.3
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249627/suppl/GSM249627.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249627-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249628">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA6204</Title>
    <Accession database="GEO">GSM249628</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
61.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 158
      </Characteristics>
      <Characteristics tag="pr">
490
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
123.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
40.5
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249628/suppl/GSM249628.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249628-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249629">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA6340</Title>
    <Accession database="GEO">GSM249629</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
72.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 52
      </Characteristics>
      <Characteristics tag="pr">
285
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
89.3
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249629/suppl/GSM249629.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249629-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249630">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA6349</Title>
    <Accession database="GEO">GSM249630</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
83.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 19
      </Characteristics>
      <Characteristics tag="pr">
154
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
121.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
56.1
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249630/suppl/GSM249630.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249630-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249631">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA6404</Title>
    <Accession database="GEO">GSM249631</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
78.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 87
      </Characteristics>
      <Characteristics tag="pr">
805
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
120.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249631/suppl/GSM249631.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249631-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249632">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA6586</Title>
    <Accession database="GEO">GSM249632</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
61.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 427
      </Characteristics>
      <Characteristics tag="pr">
513
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
117
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249632/suppl/GSM249632.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249632-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249633">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA6603</Title>
    <Accession database="GEO">GSM249633</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
53.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ICC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
10
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 26
      </Characteristics>
      <Characteristics tag="pr">
16
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
119.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249633/suppl/GSM249633.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249633-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249634">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA6660</Title>
    <Accession database="GEO">GSM249634</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
65.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ICC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 22
      </Characteristics>
      <Characteristics tag="pr">
149
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
35.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
25.7
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
35.6
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249634/suppl/GSM249634.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249634-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249635">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA7132</Title>
    <Accession database="GEO">GSM249635</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
82.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
3
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 194
      </Characteristics>
      <Characteristics tag="pr">
145
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
24
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
10
      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249635/suppl/GSM249635.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249635-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249636">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA7278</Title>
    <Accession database="GEO">GSM249636</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
61.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 67
      </Characteristics>
      <Characteristics tag="pr">
342
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
109.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249636/suppl/GSM249636.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249636-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249637">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA7280</Title>
    <Accession database="GEO">GSM249637</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
69.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ICC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
50
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT3
      </Characteristics>
      <Characteristics tag="lymph node checked">
12
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 156
      </Characteristics>
      <Characteristics tag="pr">
74
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
31.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
78.9
      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249637/suppl/GSM249637.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249637-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249638">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA7299</Title>
    <Accession database="GEO">GSM249638</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
86.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 537
      </Characteristics>
      <Characteristics tag="pr">
320
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
109.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
30
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249638/suppl/GSM249638.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249638-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249639">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VA7376</Title>
    <Accession database="GEO">GSM249639</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
73.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
17
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
3
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 418
      </Characteristics>
      <Characteristics tag="pr">
20
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
107.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249639/suppl/GSM249639.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249639-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249640">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0409</Title>
    <Accession database="GEO">GSM249640</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
76
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
4
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 52
      </Characteristics>
      <Characteristics tag="pr">
16
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
70.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249640/suppl/GSM249640.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249640-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249641">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0412</Title>
    <Accession database="GEO">GSM249641</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
79.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
Other
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 575
      </Characteristics>
      <Characteristics tag="pr">
28
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
70.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249641/suppl/GSM249641.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249641-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249642">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0416</Title>
    <Accession database="GEO">GSM249642</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
72.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
23
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 525
      </Characteristics>
      <Characteristics tag="pr">
300
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
70.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249642/suppl/GSM249642.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249642-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249643">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0419</Title>
    <Accession database="GEO">GSM249643</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
68.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 64
      </Characteristics>
      <Characteristics tag="pr">
138
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
70.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249643/suppl/GSM249643.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249643-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249644">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0421</Title>
    <Accession database="GEO">GSM249644</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
53.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 40
      </Characteristics>
      <Characteristics tag="pr">
36
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
70.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249644/suppl/GSM249644.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249644-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249646">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0431</Title>
    <Accession database="GEO">GSM249646</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
77
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
23
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
12
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
other cause
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249646/suppl/GSM249646.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249646-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249647">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0434</Title>
    <Accession database="GEO">GSM249647</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
73.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
18
      </Characteristics>
      <Characteristics tag="n+">
7
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 139
      </Characteristics>
      <Characteristics tag="pr">
43
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
46.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
9.9
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
46.8
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249647/suppl/GSM249647.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249647-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249648">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0446</Title>
    <Accession database="GEO">GSM249648</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
77.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
12
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 46
      </Characteristics>
      <Characteristics tag="pr">
15
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
69.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
36.9
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249648/suppl/GSM249648.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249648-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249649">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0449</Title>
    <Accession database="GEO">GSM249649</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
78.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
35
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
11
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 866
      </Characteristics>
      <Characteristics tag="pr">
47
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
69.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249649/suppl/GSM249649.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249649-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249650">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0451</Title>
    <Accession database="GEO">GSM249650</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
57.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
6
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 111
      </Characteristics>
      <Characteristics tag="pr">
17
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
69.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249650/suppl/GSM249650.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249650-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249651">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0452</Title>
    <Accession database="GEO">GSM249651</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
73.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
58
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT3
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 660
      </Characteristics>
      <Characteristics tag="pr">
426
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
69.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249651/suppl/GSM249651.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249651-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249652">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0463</Title>
    <Accession database="GEO">GSM249652</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
57.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
19
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
11
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
69.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249652/suppl/GSM249652.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249652-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249653">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0477</Title>
    <Accession database="GEO">GSM249653</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
79.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 184
      </Characteristics>
      <Characteristics tag="pr">
41
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249653/suppl/GSM249653.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249653-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249654">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0486</Title>
    <Accession database="GEO">GSM249654</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
59.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
16
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
39
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249654/suppl/GSM249654.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249654-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249655">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0488</Title>
    <Accession database="GEO">GSM249655</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
58.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
3
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 195
      </Characteristics>
      <Characteristics tag="pr">
148
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
44.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
deceased
      </Characteristics>
      <Characteristics tag="death cause">
recurrence
      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">
17
      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">
44.8
      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249655/suppl/GSM249655.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249655-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249657">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0492</Title>
    <Accession database="GEO">GSM249657</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
53.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 471
      </Characteristics>
      <Characteristics tag="pr">
41
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
27.8
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249657/suppl/GSM249657.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249657-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249658">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0501</Title>
    <Accession database="GEO">GSM249658</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
79.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 500
      </Characteristics>
      <Characteristics tag="pr">
222
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249658/suppl/GSM249658.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249658-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249659">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0507</Title>
    <Accession database="GEO">GSM249659</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
50.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam+LHRH
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
12
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
6
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 64
      </Characteristics>
      <Characteristics tag="pr">
76
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249659/suppl/GSM249659.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249659-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249663">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0509</Title>
    <Accession database="GEO">GSM249663</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
68.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
19
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 49
      </Characteristics>
      <Characteristics tag="pr">
92
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
68
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249663/suppl/GSM249663.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249663-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249664">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0513</Title>
    <Accession database="GEO">GSM249664</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
64.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 169
      </Characteristics>
      <Characteristics tag="pr">
145
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249664/suppl/GSM249664.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249664-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249665">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0526</Title>
    <Accession database="GEO">GSM249665</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
68.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
18
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 216
      </Characteristics>
      <Characteristics tag="pr">
50
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.7
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249665/suppl/GSM249665.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249665-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249666">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0534</Title>
    <Accession database="GEO">GSM249666</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
70.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 29
      </Characteristics>
      <Characteristics tag="pr">
19
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
35.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249666/suppl/GSM249666.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249666-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249667">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0539</Title>
    <Accession database="GEO">GSM249667</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
71.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
NA
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
35
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
18
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 762
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
26.3
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249667/suppl/GSM249667.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249667-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249668">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0541</Title>
    <Accession database="GEO">GSM249668</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
66.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
19
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 31
      </Characteristics>
      <Characteristics tag="pr">
43
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249668/suppl/GSM249668.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249668-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249669">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB0546</Title>
    <Accession database="GEO">GSM249669</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
74.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 25
      </Characteristics>
      <Characteristics tag="pr">
39
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
67.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249669/suppl/GSM249669.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249669-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249670">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1005</Title>
    <Accession database="GEO">GSM249670</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
49.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam+LHRH
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
28
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
17
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 111
      </Characteristics>
      <Characteristics tag="pr">
713
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
66.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249670/suppl/GSM249670.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249670-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249681">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1010</Title>
    <Accession database="GEO">GSM249681</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
60.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ICC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 50
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
66.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249681/suppl/GSM249681.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249681-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249682">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1022</Title>
    <Accession database="GEO">GSM249682</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
43.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam+LHRH
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
16
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 15
      </Characteristics>
      <Characteristics tag="pr">
360
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
66.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249682/suppl/GSM249682.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249682-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249683">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1028</Title>
    <Accession database="GEO">GSM249683</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
42.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam+LHRH
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
18
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
NA
      </Characteristics>
      <Characteristics tag="n+">
NA
      </Characteristics>
      <Characteristics tag="n dich+">
NA
      </Characteristics>
      <Characteristics tag="pn (tnm)">
NA
      </Characteristics>
      <Characteristics>
ER 71
      </Characteristics>
      <Characteristics tag="pr">
15
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
66
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249683/suppl/GSM249683.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249683-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249684">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1034</Title>
    <Accession database="GEO">GSM249684</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
75.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
NA
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 488
      </Characteristics>
      <Characteristics tag="pr">
786
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249684/suppl/GSM249684.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249684-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249685">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1035</Title>
    <Accession database="GEO">GSM249685</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
66.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
17
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 53
      </Characteristics>
      <Characteristics tag="pr">
29
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249685/suppl/GSM249685.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249685-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249686">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1038</Title>
    <Accession database="GEO">GSM249686</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
84.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
6
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 350
      </Characteristics>
      <Characteristics tag="pr">
44
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249686/suppl/GSM249686.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249686-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249687">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1042</Title>
    <Accession database="GEO">GSM249687</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
73.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
50
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
12
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 10
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249687/suppl/GSM249687.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249687-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249688">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1047</Title>
    <Accession database="GEO">GSM249688</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
65.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 106
      </Characteristics>
      <Characteristics tag="pr">
12
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249688/suppl/GSM249688.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249688-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249689">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1048</Title>
    <Accession database="GEO">GSM249689</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
62.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
16
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 78
      </Characteristics>
      <Characteristics tag="pr">
83
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249689/suppl/GSM249689.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249689-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249690">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1049</Title>
    <Accession database="GEO">GSM249690</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
70.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 647
      </Characteristics>
      <Characteristics tag="pr">
19
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249690/suppl/GSM249690.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249690-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249691">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1055</Title>
    <Accession database="GEO">GSM249691</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
73
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 166
      </Characteristics>
      <Characteristics tag="pr">
376
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
65.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249691/suppl/GSM249691.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249691-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249692">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1064</Title>
    <Accession database="GEO">GSM249692</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
71.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
40
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 350
      </Characteristics>
      <Characteristics tag="pr">
1198
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
64.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249692/suppl/GSM249692.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249692-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249693">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1067</Title>
    <Accession database="GEO">GSM249693</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
64.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
6
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 400
      </Characteristics>
      <Characteristics tag="pr">
437
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
64.7
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249693/suppl/GSM249693.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249693-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249694">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1073</Title>
    <Accession database="GEO">GSM249694</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
62.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
17
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
2
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 53
      </Characteristics>
      <Characteristics tag="pr">
181
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
64.6
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249694/suppl/GSM249694.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249694-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249695">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1077</Title>
    <Accession database="GEO">GSM249695</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
61.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
7
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 30
      </Characteristics>
      <Characteristics tag="pr">
50
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
64.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249695/suppl/GSM249695.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249695-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249696">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1088</Title>
    <Accession database="GEO">GSM249696</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
68.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 197
      </Characteristics>
      <Characteristics tag="pr">
348
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
64.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249696/suppl/GSM249696.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249696-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249697">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1099</Title>
    <Accession database="GEO">GSM249697</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
76.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ICC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
9
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 253
      </Characteristics>
      <Characteristics tag="pr">
41
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
63.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249697/suppl/GSM249697.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249697-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249698">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1101</Title>
    <Accession database="GEO">GSM249698</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
75.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
7
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 152
      </Characteristics>
      <Characteristics tag="pr">
132
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
63.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
39.9
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249698/suppl/GSM249698.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249698-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249699">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1122</Title>
    <Accession database="GEO">GSM249699</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
61.2
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
12
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 50
      </Characteristics>
      <Characteristics tag="pr">
136
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
63.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249699/suppl/GSM249699.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249699-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249700">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1130</Title>
    <Accession database="GEO">GSM249700</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
74.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
5
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 283
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
63.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249700/suppl/GSM249700.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249700-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249701">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1131</Title>
    <Accession database="GEO">GSM249701</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
76.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
9
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 222
      </Characteristics>
      <Characteristics tag="pr">
762
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
63.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249701/suppl/GSM249701.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249701-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249702">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1140</Title>
    <Accession database="GEO">GSM249702</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
58.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 124
      </Characteristics>
      <Characteristics tag="pr">
46
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
62.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249702/suppl/GSM249702.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249702-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249704">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1165</Title>
    <Accession database="GEO">GSM249704</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
59.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 369
      </Characteristics>
      <Characteristics tag="pr">
&lt;10
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
62.2
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249704/suppl/GSM249704.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249704-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249705">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1186</Title>
    <Accession database="GEO">GSM249705</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
80.9
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
3
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 140
      </Characteristics>
      <Characteristics tag="pr">
425
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
61.7
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
45.6
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249705/suppl/GSM249705.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249705-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249706">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1191</Title>
    <Accession database="GEO">GSM249706</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
69.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
14
      </Characteristics>
      <Characteristics tag="n+">
1
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
172
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
61.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249706/suppl/GSM249706.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249706-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249707">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1193</Title>
    <Accession database="GEO">GSM249707</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
76.5
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
50
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT3
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 232
      </Characteristics>
      <Characteristics tag="pr">
309
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
61.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249707/suppl/GSM249707.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249707-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249708">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1218</Title>
    <Accession database="GEO">GSM249708</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
92.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
22
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
8
      </Characteristics>
      <Characteristics tag="n+">
5
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
13
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
61
      </Characteristics>
      <Characteristics tag="local recurrence">
yes
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249708/suppl/GSM249708.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249708-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249709">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1225</Title>
    <Accession database="GEO">GSM249709</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
72.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
15
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 325
      </Characteristics>
      <Characteristics tag="pr">
228
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
60.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
38.8
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249709/suppl/GSM249709.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249709-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249710">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1261</Title>
    <Accession database="GEO">GSM249710</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
64.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
16
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 149
      </Characteristics>
      <Characteristics tag="pr">
315
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
59.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249710/suppl/GSM249710.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249710-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249711">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1262</Title>
    <Accession database="GEO">GSM249711</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
69.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
19
      </Characteristics>
      <Characteristics tag="n+">
5
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 45
      </Characteristics>
      <Characteristics tag="pr">
27
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
59.7
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249711/suppl/GSM249711.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249711-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249713">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1264</Title>
    <Accession database="GEO">GSM249713</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
67.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 32
      </Characteristics>
      <Characteristics tag="pr">
44
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
59.7
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249713/suppl/GSM249713.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249713-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249772">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1285</Title>
    <Accession database="GEO">GSM249772</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
74.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
17
      </Characteristics>
      <Characteristics tag="n+">
6
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 106
      </Characteristics>
      <Characteristics tag="pr">
333
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
58.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249772/suppl/GSM249772.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249772-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM249952">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1300</Title>
    <Accession database="GEO">GSM249952</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
62.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
50
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 29
      </Characteristics>
      <Characteristics tag="pr">
192
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
58.3
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM249nnn/GSM249952/suppl/GSM249952.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM249952-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250002">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1307</Title>
    <Accession database="GEO">GSM250002</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
R
      </Characteristics>
      <Characteristics tag="age">
67.4
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
ILC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 64
      </Characteristics>
      <Characteristics tag="pr">
21
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
58.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
yes
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive with meta
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250002/suppl/GSM250002.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250002-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250004">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1322</Title>
    <Accession database="GEO">GSM250004</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
81
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC+ICC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
5
      </Characteristics>
      <Characteristics tag="n+">
2
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 180
      </Characteristics>
      <Characteristics tag="pr">
153
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
57.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">
20.1
      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250004/suppl/GSM250004.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250004-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250006">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1348</Title>
    <Accession database="GEO">GSM250006</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
76.1
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
NA
      </Characteristics>
      <Characteristics tag="pt (tnm)">
NA
      </Characteristics>
      <Characteristics tag="lymph node checked">
2
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER &lt;10
      </Characteristics>
      <Characteristics tag="pr">
54
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
56.9
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250006/suppl/GSM250006.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250006-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250007">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1356</Title>
    <Accession database="GEO">GSM250007</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
81.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
25
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
ND
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 189
      </Characteristics>
      <Characteristics tag="pr">
601
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
56.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250007/suppl/GSM250007.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250007-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250009">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1357</Title>
    <Accession database="GEO">GSM250009</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
42.6
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam+LHRH
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
5
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 86
      </Characteristics>
      <Characteristics tag="pr">
129
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
56.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250009/suppl/GSM250009.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250009-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250010">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1359</Title>
    <Accession database="GEO">GSM250010</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
81.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 129
      </Characteristics>
      <Characteristics tag="pr">
12
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
56.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250010/suppl/GSM250010.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250010-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250011">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1361</Title>
    <Accession database="GEO">GSM250011</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
62.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
10
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 137
      </Characteristics>
      <Characteristics tag="pr">
1097
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
56.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250011/suppl/GSM250011.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250011-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250012">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1362</Title>
    <Accession database="GEO">GSM250012</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
82.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
Other
      </Characteristics>
      <Characteristics tag="sbr grade">
1
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
17
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
3
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 63
      </Characteristics>
      <Characteristics tag="pr">
415
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
56.4
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250012/suppl/GSM250012.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250012-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250013">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1372</Title>
    <Accession database="GEO">GSM250013</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
52.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
15
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT1
      </Characteristics>
      <Characteristics tag="lymph node checked">
2
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 125
      </Characteristics>
      <Characteristics tag="pr">
224
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
56.1
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250013/suppl/GSM250013.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250013-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250014">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1390</Title>
    <Accession database="GEO">GSM250014</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
79
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
Other
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
43
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
13
      </Characteristics>
      <Characteristics tag="n+">
3
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 198
      </Characteristics>
      <Characteristics tag="pr">
115
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
55.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250014/suppl/GSM250014.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250014-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250015">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1391</Title>
    <Accession database="GEO">GSM250015</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
66.8
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
20
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 283
      </Characteristics>
      <Characteristics tag="pr">
1526
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
55.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250015/suppl/GSM250015.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250015-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250016">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1397</Title>
    <Accession database="GEO">GSM250016</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
66.3
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
22
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
24
      </Characteristics>
      <Characteristics tag="n+">
3
      </Characteristics>
      <Characteristics tag="n dich+">
1
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN1
      </Characteristics>
      <Characteristics>
ER 271
      </Characteristics>
      <Characteristics tag="pr">
102
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
55.5
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250016/suppl/GSM250016.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250016-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250017">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1409</Title>
    <Accession database="GEO">GSM250017</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
73
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
45
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT4
      </Characteristics>
      <Characteristics tag="lymph node checked">
29
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 179
      </Characteristics>
      <Characteristics tag="pr">
859
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
55.2
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250017/suppl/GSM250017.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250017-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Sample iid="GSM250018">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>VB1411</Title>
    <Accession database="GEO">GSM250018</Accession>
    <Type>RNA</Type>
    <Channel-Count>1</Channel-Count>
    <Channel position="1">
      <Source>Breast primary tumor</Source>
      <Organism taxid="9606">Homo sapiens</Organism>
      <Characteristics tag="status">
RF
      </Characteristics>
      <Characteristics tag="age">
62.7
      </Characteristics>
      <Characteristics tag="adjuvant therapy">
X-ray+Tam
      </Characteristics>
      <Characteristics tag="histological type">
IDC
      </Characteristics>
      <Characteristics tag="sbr grade">
2
      </Characteristics>
      <Characteristics tag="tumor size (mm)">
30
      </Characteristics>
      <Characteristics tag="pt (tnm)">
pT2
      </Characteristics>
      <Characteristics tag="lymph node checked">
11
      </Characteristics>
      <Characteristics tag="n+">
0
      </Characteristics>
      <Characteristics tag="n dich+">
0
      </Characteristics>
      <Characteristics tag="pn (tnm)">
pN0
      </Characteristics>
      <Characteristics>
ER 427
      </Characteristics>
      <Characteristics tag="pr">
912
      </Characteristics>
      <Characteristics tag="follow-up period (months)">
54.8
      </Characteristics>
      <Characteristics tag="local recurrence">
no
      </Characteristics>
      <Characteristics tag="distant metastases">
no
      </Characteristics>
      <Characteristics tag="time before recurrence (months)">

      </Characteristics>
      <Characteristics tag="state of health">
alive
      </Characteristics>
      <Characteristics tag="death cause">

      </Characteristics>
      <Characteristics tag="decease delay upon recurrence (months)">

      </Characteristics>
      <Characteristics tag="decease delay after surgery (months)">

      </Characteristics>
      <Molecule>total RNA</Molecule>
      <Extract-Protocol>
Frozen breast tumors (40 mg) were homogenized using the FastPrep System from Q-Biogene. Total RNA was extracted and cleaned up from the lysate with use of the Qiagen RNeasy Mini Kit. The RNA purity and integrity was controlled by way of the Bioanalyser 2100 (Agilent). 									
      </Extract-Protocol>
      <Label>Cy5</Label>
      <Label-Protocol>
For each sample, 2 µg of total RNA was reverse-transcribed and amplified by using the RNA amplification kit from Ambion. Fifteen µg of amplified RNA were labelled by direct chemical coupling to the Cy5 NHS ester (Amersham Biosciences).									
      </Label-Protocol>
    </Channel>
    <Hybridization-Protocol>
Labelled RNAs were purified, fragmented and used as probes to hybridize microarrays. 									
    </Hybridization-Protocol>
    <Scan-Protocol>
Fluorescent images of hybridized microarrays were obtained with Axon 4000B scanner and analyzed using Genepix 6.0. The mean of replicated spots was calculated for each gene by using the Acuity 4.0 software. 									
    </Scan-Protocol>
    <Description>
Tumor samples from Tamoxifen-only treated primary breast cancer patients.
    </Description>
    <Data-Processing>
Data were median centered and log2 transformed.
    </Data-Processing>
    <Platform-Ref ref="GPL5049" />
    <Contact-Ref ref="contrib1" />
    <Supplementary-Data type="GPR">
ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM250nnn/GSM250018/suppl/GSM250018.gpr.gz
    </Supplementary-Data>
    <Data-Table>
      <Column position="1">
        <Name>ID_REF</Name>
      </Column>
      <Column position="2">
        <Name>VALUE</Name>
        <Description>log F635 norm</Description>
      </Column>
    <External-Data rows="22656">
GSM250018-tbl-1.txt
    </External-Data>
    </Data-Table>
  </Sample>

  <Series iid="GSE9893">
    <Status database="GEO">
      <Submission-Date>2007-12-14</Submission-Date>
      <Release-Date>2008-03-18</Release-Date>
      <Last-Update-Date>2015-10-08</Last-Update-Date>
    </Status>
    <Title>A gene expression signature predicting the recurrence of tamoxifen-treated primary breast cancer.</Title>
    <Accession database="GEO">GSE9893</Accession>
    <Pubmed-ID>18347175</Pubmed-ID>
    <Summary>
A 36-gene classifier was constructed through expression profiling of 132 tumors  from tamoxifen-treated patients using 70-mer oligonucleotide microarrays. The robustness of the signature was demonstrated using expression data from 83 independent tumors. The 36-gene signature was (i) more efficient to predict disease-free survival than the traditional histo-pathological prognostic factors, (ii) as effective as the Nottingham Prognostic Index or the &quot;Adjuvant!&quot; software, and (iii) the only independent prognostic factor. Comparison with several already published signatures demonstrated that the 36-gene signature was among the best to classify tumors.
Keywords: Gene expression profiling; supervised analysis; molecular signature predictive of recurrence; univariate and multivariate analysis in relation to disease-free survival.
    </Summary>
    <Overall-Design>
In the study presented here, a cohort of 132 primary tumors from tamoxifen-treated patients followed up more than 5-years, was used to acquire expression profiles at the whole genome level by 70-mer oligonucleotide microarrays containing 22,680 probes (which represent 21,329 human specific genes). Supervised predictive analysis of microarrays allowed construction of a 36-gene molecular classifier whose robustness was assessed by using gene expression data from 83 independent tumors (including 23 tumors from our microarray platform and 60 tumors from the study by Ma et al., Cancer cell 2004; 5:607-616).
    </Overall-Design>
    <Type>Expression profiling by array</Type>
    <Contributor-Ref ref="contrib6" position="1" />
    <Contributor-Ref ref="contrib7" position="2" />
    <Contributor-Ref ref="contrib8" position="3" />
    <Contributor-Ref ref="contrib9" position="4" />
    <Contributor-Ref ref="contrib10" position="5" />
    <Contributor-Ref ref="contrib11" position="6" />
    <Contributor-Ref ref="contrib12" position="7" />
    <Contributor-Ref ref="contrib13" position="8" />
    <Contributor-Ref ref="contrib14" position="9" />
    <Contributor-Ref ref="contrib15" position="10" />
    <Contributor-Ref ref="contrib16" position="11" />
    <Contact-Ref ref="contrib1" />
    <Sample-Ref ref="GSM249296" />
    <Sample-Ref ref="GSM249524" />
    <Sample-Ref ref="GSM249527" />
    <Sample-Ref ref="GSM249529" />
    <Sample-Ref ref="GSM249530" />
    <Sample-Ref ref="GSM249531" />
    <Sample-Ref ref="GSM249532" />
    <Sample-Ref ref="GSM249533" />
    <Sample-Ref ref="GSM249534" />
    <Sample-Ref ref="GSM249535" />
    <Sample-Ref ref="GSM249536" />
    <Sample-Ref ref="GSM249537" />
    <Sample-Ref ref="GSM249538" />
    <Sample-Ref ref="GSM249539" />
    <Sample-Ref ref="GSM249540" />
    <Sample-Ref ref="GSM249541" />
    <Sample-Ref ref="GSM249542" />
    <Sample-Ref ref="GSM249543" />
    <Sample-Ref ref="GSM249544" />
    <Sample-Ref ref="GSM249545" />
    <Sample-Ref ref="GSM249546" />
    <Sample-Ref ref="GSM249547" />
    <Sample-Ref ref="GSM249548" />
    <Sample-Ref ref="GSM249549" />
    <Sample-Ref ref="GSM249551" />
    <Sample-Ref ref="GSM249552" />
    <Sample-Ref ref="GSM249553" />
    <Sample-Ref ref="GSM249555" />
    <Sample-Ref ref="GSM249556" />
    <Sample-Ref ref="GSM249557" />
    <Sample-Ref ref="GSM249558" />
    <Sample-Ref ref="GSM249559" />
    <Sample-Ref ref="GSM249560" />
    <Sample-Ref ref="GSM249561" />
    <Sample-Ref ref="GSM249563" />
    <Sample-Ref ref="GSM249564" />
    <Sample-Ref ref="GSM249565" />
    <Sample-Ref ref="GSM249566" />
    <Sample-Ref ref="GSM249567" />
    <Sample-Ref ref="GSM249595" />
    <Sample-Ref ref="GSM249596" />
    <Sample-Ref ref="GSM249597" />
    <Sample-Ref ref="GSM249598" />
    <Sample-Ref ref="GSM249599" />
    <Sample-Ref ref="GSM249600" />
    <Sample-Ref ref="GSM249601" />
    <Sample-Ref ref="GSM249602" />
    <Sample-Ref ref="GSM249603" />
    <Sample-Ref ref="GSM249604" />
    <Sample-Ref ref="GSM249605" />
    <Sample-Ref ref="GSM249606" />
    <Sample-Ref ref="GSM249607" />
    <Sample-Ref ref="GSM249608" />
    <Sample-Ref ref="GSM249609" />
    <Sample-Ref ref="GSM249610" />
    <Sample-Ref ref="GSM249611" />
    <Sample-Ref ref="GSM249612" />
    <Sample-Ref ref="GSM249613" />
    <Sample-Ref ref="GSM249614" />
    <Sample-Ref ref="GSM249615" />
    <Sample-Ref ref="GSM249616" />
    <Sample-Ref ref="GSM249617" />
    <Sample-Ref ref="GSM249618" />
    <Sample-Ref ref="GSM249619" />
    <Sample-Ref ref="GSM249620" />
    <Sample-Ref ref="GSM249622" />
    <Sample-Ref ref="GSM249623" />
    <Sample-Ref ref="GSM249624" />
    <Sample-Ref ref="GSM249625" />
    <Sample-Ref ref="GSM249627" />
    <Sample-Ref ref="GSM249628" />
    <Sample-Ref ref="GSM249629" />
    <Sample-Ref ref="GSM249630" />
    <Sample-Ref ref="GSM249631" />
    <Sample-Ref ref="GSM249632" />
    <Sample-Ref ref="GSM249633" />
    <Sample-Ref ref="GSM249634" />
    <Sample-Ref ref="GSM249635" />
    <Sample-Ref ref="GSM249636" />
    <Sample-Ref ref="GSM249637" />
    <Sample-Ref ref="GSM249638" />
    <Sample-Ref ref="GSM249639" />
    <Sample-Ref ref="GSM249640" />
    <Sample-Ref ref="GSM249641" />
    <Sample-Ref ref="GSM249642" />
    <Sample-Ref ref="GSM249643" />
    <Sample-Ref ref="GSM249644" />
    <Sample-Ref ref="GSM249646" />
    <Sample-Ref ref="GSM249647" />
    <Sample-Ref ref="GSM249648" />
    <Sample-Ref ref="GSM249649" />
    <Sample-Ref ref="GSM249650" />
    <Sample-Ref ref="GSM249651" />
    <Sample-Ref ref="GSM249652" />
    <Sample-Ref ref="GSM249653" />
    <Sample-Ref ref="GSM249654" />
    <Sample-Ref ref="GSM249655" />
    <Sample-Ref ref="GSM249657" />
    <Sample-Ref ref="GSM249658" />
    <Sample-Ref ref="GSM249659" />
    <Sample-Ref ref="GSM249663" />
    <Sample-Ref ref="GSM249664" />
    <Sample-Ref ref="GSM249665" />
    <Sample-Ref ref="GSM249666" />
    <Sample-Ref ref="GSM249667" />
    <Sample-Ref ref="GSM249668" />
    <Sample-Ref ref="GSM249669" />
    <Sample-Ref ref="GSM249670" />
    <Sample-Ref ref="GSM249681" />
    <Sample-Ref ref="GSM249682" />
    <Sample-Ref ref="GSM249683" />
    <Sample-Ref ref="GSM249684" />
    <Sample-Ref ref="GSM249685" />
    <Sample-Ref ref="GSM249686" />
    <Sample-Ref ref="GSM249687" />
    <Sample-Ref ref="GSM249688" />
    <Sample-Ref ref="GSM249689" />
    <Sample-Ref ref="GSM249690" />
    <Sample-Ref ref="GSM249691" />
    <Sample-Ref ref="GSM249692" />
    <Sample-Ref ref="GSM249693" />
    <Sample-Ref ref="GSM249694" />
    <Sample-Ref ref="GSM249695" />
    <Sample-Ref ref="GSM249696" />
    <Sample-Ref ref="GSM249697" />
    <Sample-Ref ref="GSM249698" />
    <Sample-Ref ref="GSM249699" />
    <Sample-Ref ref="GSM249700" />
    <Sample-Ref ref="GSM249701" />
    <Sample-Ref ref="GSM249702" />
    <Sample-Ref ref="GSM249704" />
    <Sample-Ref ref="GSM249705" />
    <Sample-Ref ref="GSM249706" />
    <Sample-Ref ref="GSM249707" />
    <Sample-Ref ref="GSM249708" />
    <Sample-Ref ref="GSM249709" />
    <Sample-Ref ref="GSM249710" />
    <Sample-Ref ref="GSM249711" />
    <Sample-Ref ref="GSM249713" />
    <Sample-Ref ref="GSM249772" />
    <Sample-Ref ref="GSM249952" />
    <Sample-Ref ref="GSM250002" />
    <Sample-Ref ref="GSM250004" />
    <Sample-Ref ref="GSM250006" />
    <Sample-Ref ref="GSM250007" />
    <Sample-Ref ref="GSM250009" />
    <Sample-Ref ref="GSM250010" />
    <Sample-Ref ref="GSM250011" />
    <Sample-Ref ref="GSM250012" />
    <Sample-Ref ref="GSM250013" />
    <Sample-Ref ref="GSM250014" />
    <Sample-Ref ref="GSM250015" />
    <Sample-Ref ref="GSM250016" />
    <Sample-Ref ref="GSM250017" />
    <Sample-Ref ref="GSM250018" />
    <Supplementary-Data type="TAR">
ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE9nnn/GSE9893/suppl/GSE9893_RAW.tar
    </Supplementary-Data>
    <Supplementary-Data type="TXT">
ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE9nnn/GSE9893/suppl/GSE9893_clinicalData.txt
    </Supplementary-Data>
    <Relation type="BioProject" target="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA103889" />
  </Series>

</MINiML>
